Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep618 | Pituitary and Neuroendocrinology | ECE2020

Efficacy, safety and pitfalls of glucocorticoid therapy for patients with autoimmune hypophysitis

Tatsushima Keita , Takeshita Akira , Fukuhara Noriaki , Yamaguchi-Okada Mitsuo , Fukuhara Hirokazu , Nishioka Hiroshi , Takeuchi Yasuhiro

Background and aim: Autoimmune hypophysitis (AH) is a rare immune-mediated inflammatory disease. Glucocorticoid therapy represents a therapeutic choice for AH patients with symptoms from mass effect, such as headache and optic nerve compression. However, effective methods and adverse events of glucocorticoid therapy are unclear. We aimed to evaluate the efficacy and safety of glucocorticoid therapy in AH patients.Patients and Methods: The subjects were a...

ea0099oc2.2 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial

Schwarz Peter , Rejnmark Lars , Gosmanova Elvira , Khan Aliya , Makita Noriko , Imanishi Yasuo , Takeuchi Yasuhiro , Sprague Stuart , Shoback Dolores M. , Kohlmeier Lynn , Rubin Mishaela , Palermo Andrea , Gagnon Claudia , Tsourdi Elena , Zhao Carol , Makara Michael , Ominsky Michael , Lai Bryant , Ukena Jenny , Sibley Christopher , Shu Aimee

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) are at increased risk for renal complications and declines in renal function. In clinical trials, palopegteriparatide treatment enabled independence from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and maintained serum biochemistr...